Pharmacokinetic/Pharmacodynamic Characteristics and Safety/Tolerability of MT921 in Healthy Subjects

Medytox

Status and phase: Completed; Phase 1

Conditions: Healthy Volunteers

Treatments: Drug: MT921; Drug: Placebo

Study type: Interventional

Funder types: Industry

Identifiers

NCT03905291

MT11-KR17SMF115

Details and patient eligibility

About

To determine the pharmacokinetic/pharmacodynamic characteristics and safety/tolerability of MT921 in Healthy Subjects

Enrollment: 25 patients

Sex: All

Ages: 20 to 65 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Adults aged between 20 and 65 years

Exclusion criteria

• Subject not appropriate for participating in this study according to the investigator's opinion

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind

---

25 participants in 4 patient groups, including a placebo group

MT921 60mg Group

Experimental group

Description:

MT921 60 mg

Treatment:

Drug: MT921

MT921 120mg Group

Experimental group

Description:

MT921 120 mg

Treatment:

Drug: MT921

MT921 150mg Group

Experimental group

Description:

MT921 150 mg

Treatment:

Drug: MT921

Placebo Group

Placebo Comparator group

Description:

Placebo

Treatment:

Drug: Placebo